ESR1 and breast cancer: Recently, a new IGF-1 monoclonal antibody, Xentuzumab (Xen) has been investigated in the phase II XENERA-1 trial in combination with Ev and exemestane (Ex) in post-menopausal women with ER+ and HER2− metastatic BC (Crown et al., 2019).